Prepulse inhibition during withdrawal from an escalating dosage schedule of amphetamine.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 340, doi. 10.1007/s00213-002-1254-4
- By:
- Publication type:
- Article
Works matching IS 00333158 AND DT 2003 AND VI 169 AND IP 3/4
Results: 20
1
2
Cognitive rehabilitation in schizophrenia: a quantitative analysis of controlled studies.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 376, doi. 10.1007/s00213-002-1326-5
- By:
- Publication type:
- Article
3
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 404, doi. 10.1007/s00213-002-1342-5
- By:
- Publication type:
- Article
4
The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 257, doi. 10.1007/s00213-002-1313-x
- By:
- Publication type:
- Article
5
Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 314, doi. 10.1007/s00213-002-1325-6
- By:
- Publication type:
- Article
6
Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 240, doi. 10.1007/s00213-003-1421-2
- By:
- Publication type:
- Article
7
Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 308, doi. 10.1007/s00213-003-1461-7
- By:
- Publication type:
- Article
8
Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 383, doi. 10.1007/s00213-003-1476-0
- By:
- Publication type:
- Article
9
Cognition in schizophrenia: from basic science to clinical treatment.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 213, doi. 10.1007/s00213-003-1581-0
- By:
- Publication type:
- Article
10
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 390, doi. 10.1007/s00213-003-1505-z
- By:
- Publication type:
- Article
11
Differential effects of iloperidone, clozapine, and haloperidol on working memory of rats in the delayed non-matching-to-position paradigm.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 354, doi. 10.1007/s00213-003-1459-1
- By:
- Publication type:
- Article
12
Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 298, doi. 10.1007/s00213-003-1460-8
- By:
- Publication type:
- Article
13
Right-hemisphere encephalopathy in elderly subjects with schizophrenia: evidence from neuropsychological and brain imaging studies.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 367, doi. 10.1007/s00213-003-1524-9
- By:
- Publication type:
- Article
14
DMXB, an α[sub 7] nicotinic agonist, normalizes auditory gating in isolation-reared rats.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 332, doi. 10.1007/s00213-003-1482-2
- By:
- Publication type:
- Article
15
Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 365, doi. 10.1007/s00213-003-1564-1
- By:
- Publication type:
- Article
16
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 215, doi. 10.1007/s00213-003-1582-z
- By:
- Publication type:
- Article
17
Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 321, doi. 10.1007/s00213-002-1173-4
- By:
- Publication type:
- Article
18
Effects of NRA0045, a novel potent antagonist at dopamine D[sub 4,] 5-HT[sub 2A], and α[sub 1] adrenaline receptors, and NRA0160, a selective D[sub 4] receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 247, doi. 10.1007/s00213-003-1517-8
- By:
- Publication type:
- Article
19
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 398, doi. 10.1007/s00213-003-1506-y
- By:
- Publication type:
- Article
20
Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys Antipsychotic effects on PPI deficits in monkeys.
- Published in:
- Psychopharmacology, 2003, v. 169, n. 3/4, p. 234, doi. 10.1007/s00213-003-1533-8
- By:
- Publication type:
- Article